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Background: The research goal is to better understand prescriber, patient, and caregiver perspectives about
long-acting injectable (LAI) antipsychotic therapy and how these perspectives affect LAI use. Addressing these
perspectives in the clinic may lead to greater success in achieving therapeutic goals for the patient with
schizophrenia.
Methods: Ethnographic information was collected from a non-random sample of 69 prescriber-patient
conversations (60 with community mental health center [CMHC] psychiatrists; 9 with nurse-practitioners) recorded
during treatment visits from August 2011 to February 2012, transcribed and analyzed. Discussions were categorized
according to 11 predetermined CMHC topics. In-person observations were also conducted at 4 CMHCs, including
home visits by researchers (n = 15 patients) prior to the CMHC visit and observations of patients receiving injections
and interacting with staff. Telephone in-depth interviews with psychiatrists, patients, and caregivers to gather
additional information on LAI discussion, prescription, or use were conducted.
Results: Antipsychotic treatment decisions were made without patient or caregiver input in 40 of 60 (67%) of
psychiatrist-patient conversations. Involvement of patients or caregivers in treatment decisions was greater when
discussing LAI (15 of 60 [25%]) vs oral antipsychotic treatment (5 of 60 [8%]). LAIs were not discussed by
psychiatrists in 11 of 22 (50%) patients taking oral antipsychotics. When offered, more LAI-naïve patients expressed
neutral (9 of 19 [47%]) rather than favorable (3 of 19 [16%]) or unfavorable (7 of 19 [37%]) responses. Prescribers
were most concerned about potentially damaging the therapeutic relationship and side-effects when discussing
LAIs while patient resistance was often related to negative feelings about injections. Psychiatrists had some success
in overcoming patient objections to LAIs by addressing and decomposing initial resistance. More than half (11 of
19 [58%]) of LAI-naïve patients agreed to start LAI treatment following office visits. Patient-described benefits of LAIs
vs orals included perceived rapid symptom improvement and greater overall efficacy.
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Conclusions: In this study, many psychiatrists did not offer LAIs and most patients and caregivers were not
involved in antipsychotic treatment decision making. Opportunities to increase active patient engagement, address
resistances, guide patient drug-formulation selection, and provide better LAI-relevant information for more
individualized approaches to treating the patient with schizophrenia were present.
Keywords: Long-acting injectable antipsychotics, Patient perspectives, Prescriber perspectives, Schizophrenia,
Treatment benefits, Community mental health, Office-visit discussions, Patient attitudes, Psychiatrists attitudes,
Depot antipsychotics, EthnographicBackground
Schizophrenia can be thought of as a group of chronic
disorders that are often neurodevelopmentally based and
marked by progressive brain changes, tissue loss (both
gray and white matter), and increases in ventricular
volume [1] that have been associated with functional
impairment [2] and increased hospitalization rates [3].
Long durations of untreated psychosis are associated
with more widespread symptomatology, lower quality of
life, and may also lead to a lower chance of achieving re-
mission [4,5]. Patients may show decreased responsive-
ness to treatment following a relapse [6] and increased
time to remission may occur with each subsequent re-
lapse [7]. The highest chance of remission or recovery is
at the first episode [8] and with continued treatment [9].
These conclusions, along with findings that certain anti-
psychotics have been associated with attenuation of fre-
quently observed brain grey matter loss [3], suggest that
rapid and consistent treatment may help avoid accumu-
lation of permanent disability.
The definition of medication adherence or compliance
varies in the literature but has been recently defined
as ≥80% of medications taken (over 12 months) and/
or <1 week of missed medications (over 3 months) [10].
Adherence is important for effective treatment and re-
lapse prevention. Recent surveys suggest that, on aver-
age, experts believe patients with schizophrenia only
take 51% to 70% of their prescribed medications [10],
with only 40% to 60% of patients remaining adherent to
treatment long-term [11]. Even these numbers may be
optimistic as adherence statistics are often based on self-
reporting due to a lack of available objective and accu-
rate measures [10].
Adherence can be a significant predictor of recovery
among schizophrenia patients [12]. Remaining on anti-
psychotic medication can lead to long-standing remis-
sions and improved quality of life [9]. Nonadherent
patients are over 10 times more likely to have a psy-
chotic relapse and 4 times more likely to be hospitalized
than adherent patients [13]. Reduced adherence can also
complicate treatment assessments based on the inabi-
lity to discern whether poor outcomes stem from the
choice of medications or from failure to take them asprescribed [10]. These detrimental effects on clinical
outcomes are also a significant factor on health care
burden. In 2005, rehospitalization costs related to an-
tipsychotic nonadherence in the United States (US)
ranged from $1.4–$1.8 billion [14]. In one study,
nearly 30% of partially or fully nonadherent patients
were hospitalized over 1 year compared with 17% of
adherent patients [15]. The average length of hospital
stay for nonadherent, partially adherent, and adherent
patients was 18 days, 30 days, and 9 days, respec-
tively [15].
Factors that contribute to medication compliance in-
clude: cognitive deficits, perceived or actual side effects,
lack of patient insight, poor efficacy, lack of social sup-
port, problems with the therapeutic alliance, cultural or
religious beliefs, complexity of daily treatment regimens,
and drug abuse among others [10,16]. Environmental
factors like unstable living situations, lack of insurance
or financial issues, and difficulty with access to treat-
ment can also influence adherence [10].
Long-acting injectable antipsychotics (LAIs), which
are administered once every 2 or 4 weeks (depending on
the specific drug) rather than daily, are one option to
help address nonadherence. LAIs have been associated
with both reduced hospitalization rates and care costs
[17-19]. Clinical guidelines on LAI usage have been pub-
lished, recommending that LAIs should not only be used
to address nonadherence but also if patients have a basic
preference for this formulation––for convenience or any
other reason [20-22]. Yet, LAIs continue to be under-
used and are often reserved for only the most severely
affected/nonadherent patients. Despite a low adherence
rate with oral medication overall [11], US prescription
rates for LAIs have been estimated at only 8% of schizo-
phrenia patients receiving treatment (estimated from the
IMS Multinational Integrated Data Analysis System
database, Q3 2011–Q2 2012 [e-mail communication to
the author from Ray Lansigan of Rosetta–a marketing re-
search organization (ray.lansigan@rosetta.com), February
13, 2013]). In contrast, surveys in the United Kingdom,
Belgium, Hong Kong, and Australia have found LAI use
to vary between 22% and 36% of patients prescribed an
antipsychotic [23-26].
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tacles to using LAIs. A recent systematic literature
review of publications from June 1999 to the end of
February 2008 found that only 1 out of 5 evaluated stu-
dies showed positive patient attitudes towards LAIs (the
remaining 4 were divided evenly between neutral and
negative attitudes) [27]. In comparison, health care pro-
fessionals (HCPs) had more favorable opinions about
LAIs, with 4 of 7 studies reporting positive attitudes
[27]. These findings were supported by survey results
that showed patients had less favorable views of LAIs
than psychiatrists or caregivers [28]. Interestingly, a
strong positive relationship was identified between pa-
tient attitudes and prior experience with LAIs. Positive
perceptions were indicated by 23% of LAI-naïve patients,
45% who had previously received LAIs, and 73% cur-
rently taking LAIs [29], suggesting experience with LAIs
significantly affects perspectives on treatment with LAIs.
For psychiatrists, there seems to be a positive rela-
tionship between level of knowledge about LAIs and at-
titude toward LAIs [30]. Among psychiatrists, despite a
minority expressing negative attitudes such as feeling
that LAIs might require coercion or be viewed as old-
fashioned or stigmatizing [30], most prescribers ex-
pressed favorable attitudes about LAI formulations,
particularly for patients with adherence or relapse issues
[30]. However, this support does not appear to translate
into practice because approximately 9 out of 10 psychia-
trists endorse oral formulations over LAIs [28].
This study was designed to examine contemporary ac-
tual office visit interactions between patients, caregivers,
and prescribers to further understand and characterize
the dynamic interaction between prescriber and patient
perspectives on the use of LAIs for the treatment of
schizophrenia. The overall goal is to facilitate better cli-
nical understanding of the obstacles surrounding use of
LAIs and describe successful approaches to offering this
formulation option to realize greater success in clinical
outcomes and achieving therapeutic goals.Methods
Health care professional/patient recorded conversations
Psychiatrists who worked in a community mental health
center (CMHC) were selected from a panel previously
identified to participate in ethnographic research (ie, a
non-random, self-selected sample). Nurse practitioners
(NPs), social workers, and therapists were recruited by
telephone. All professional participants completed a
screening questionnaire to ensure qualification for the
study. HCPs provided study information to patients and
Health Insurance Portability and Accountability Act
(HIPAA) informed consent was acquired from all study
participants. HCP participants were compensated forrecording their visits with patients and patients were not
compensated during this phase of the research.
Psychiatrists and NPs were included if ≥50% of their
practice occurred in a CMHC, they treated patients with
schizophrenia, and prescribed LAIs for at least some
patients. Other HCPs (eg, social workers) were included
if >20% of their time was spent in a CMHC and they
worked with patients with schizophrenia. Patients in the
study had a primary diagnosis of schizophrenia and were
indicated for a change in treatment. Patients with a pri-
mary diagnosis other than schizophrenia, those who
were non-English speaking, or who could not provide
informed consent due to cognitive impairment were
excluded.
Conversations between patients or their caregivers and
HCPs from across the US were recorded during treat-
ment visits between August 2011 and February 2012.
Conversations were transcribed and analyzed. Discus-
sions were categorized according to 11 main predeter-
mined topics occurring during a typical CMHC visit for
patients with schizophrenia (Figure 1).
A total of 2–4 team members (consisting of 2 medical
information researchers and 2 linguists/cultural anthro-
pologists) concurrently analyzed the recorded conversa-
tions by reading and listening to each dialogue. Analyses
were descriptive and qualitative. Qualitative and linguis-
tic analysis was conducted utilizing a mix of analytical
methods including “constant comparison” [31]. Constant
comparison is a method that structures analysis of con-
versational dynamics, lexicon, themes, and meaning
across a corpus of data and within cohorts. In constant
comparison, the analyst selects 2 data points (here,
HCP-patient/caregiver conversations) and analyzes first
one side and then the other, for conversational dyna-
mics, lexicon, emergent themes, and essential meanings.
Then, the second conversation is analyzed in the same
way, noting similarities and differences between the 2
conversations in a spreadsheet and within the texts
themselves, such that a rich log of findings and com-
parative points is constructed and maintained. The ana-
lyst then proceeds with a third data point (ie, one side of
the next conversation pair), comparing findings from
that text to the prior 2 texts and notes any differences or
similarities among all 3. Then the analyst compares the
fourth data point to findings from analysis of the first 3.
This proceeds across the corpus of data within a cohort.
Constant comparison is then conducted in other cohorts
in this manner. Findings from all cohorts are then com-
pared and contrasted to identify essential differences be-
tween and among cohorts.
Further telephone in-depth interviews
Further telephone in-depth interviews (TDIs) with psy-
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Figure 1 Topics discussed as percent of prescriber-patient community mental health center office visits (n = 69). (Total does not equal
100% due to some language/discussion not falling under 1 of topics).
Potkin et al. BMC Psychiatry 2013, 13:261 Page 4 of 11
http://www.biomedcentral.com/1471-244X/13/261and caregivers (n = 4) also were conducted to gather
follow-up information on LAI discussion, prescription,
or use. During TDIs with psychiatrists, audio clips from
actual conversations from the patient meeting were
played back to gain deeper insight into thought pro-
cesses during the conversations.
In-person community mental health center observation
Separately, 4 CMHCs (located in Chicago, IL; Atlanta,
GA; Warren, OH; and St. Petersburg, FL) were recruited
for in-person observations that took place between
December 2011 and February 2012. CMHC psychia-
trists provided study information to patients and pa-
tients then had to contact study investigators if interested
in participating. Informed consent was acquired from all
participants in the study. Professional participant and pa-
tient/caregiver information collected was made anonym-
ous prior to analysis. The study protocol was approved by
the independent New England Investigational Review
Board. HCPs were not compensated for their partici-
pation, however, the CMHC was provided with a $1500
donation. Patients received a $25 local gift card for par-
ticipating in the in-person observations.
The research was carried out by teams of 1–2 trained
anthropologists. Anthropology researchers spent a few
hours at home with some patients prior to their CMHC
visit, discussing each patient’s disease and treatment ex-
periences, then followed the patient to the CMHC and
observed any meetings with the psychiatrist or nurse,
the patient receiving an injection, and any other in-
teractions within the clinic. A total of 15 patient in-
home visits, with 10 patients receiving LAIs and 5
receiving oral medications (12 men and 3 women)
were conducted.Results
Patient and prescriber (or other health care professional)
conversations
Prescriber conversations (n = 60 with 14 psychiatrists;
n = 9 with 2 NPs) averaged 11.5 minutes in total dur-
ation. Duration of interaction varied individually by type
of HCP, averaging 12 minutes with psychiatrists, 9 mi-
nutes with NPs, and 16.6 minutes with social workers or
therapists (4 conversations from 2 social workers and 2
therapists). Conversations between all types of HCPs
and patients or caregivers comprised 2 phases: assess-
ment and decision, which each covered approximately
70% and 30% of conversation time, respectively. During
the assessment phase of the conversation, patients and/
or caregivers dominated the conversation and then gen-
erally yielded to HCPs for the decision phase.
Multiple treatment goals were pursued for patients
with schizophrenia and were addressed differently by
each type of HCP. Social workers and therapists used
open-ended questions (“What would you like to talk
about?” “What would you like to work on?”) and primar-
ily focused on issues like social wellness and means of
achieving daily structure, like work or school. Patients or
caregivers sometimes discussed medications and compli-
ance during these sessions but were not explicitly fo-
cused on this topic. Prescribers typically used a scripted
check-list approach to ensure assessment for positive
symptoms, deviating only if positive symptoms were
detected and required further investigation. Figure 1
shows a breakdown of the types of topics discussed be-
tween prescribers and patients. Treatment discussion
and behavior modification/counseling occupied just over
50% of the prescriber-patient visit. Psychiatrists and NPs
spent a similar amount of time on treatment discussion
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seling is attributed more to psychiatrists (25% vs 1% for
NPs). Discussion on compliance occupied only 2% of the
prescriber-patient visit. During conversations about
medications, prescribers asked simple, direct questions
when probing for patient medication compliance (“Are
you taking your medications?” “Did you take any medi-
cine last night…?”). Prescribers used direct and logical
strategies when probing adherence but could become
more authoritative upon discovering noncompliance.
Overall conversation flow generally started with pres-
cribers probing for compliance, symptoms, and assessing
treatment, which may have included a subjective illness
narrative by the patient. The second phase was led by
patients where they could express any treatment prefer-
ences. The final phase consisted of prescriber-led treat-
ment planning and LAI scheduling (if selected) based on
learnings from the earlier phases of the conversation
(Figure 2).
Health care professional and patient characteristics
A total of 20 unique HCPs (psychiatrists, n = 14; nurse
practitioners, n = 2; case/social workers, n = 2; therapists,
n = 2) from 16 unique institutions across the United
States participated in the study.
Psychiatrists (n = 14) and their patients (n = 60) pro-
vided the most complete set of information for the study
including recorded conversations, TDIs, and in-person
CMHC observations. Psychiatrists’ patients were being
treated with oral antipsychotics (n = 22) or LAIs (n = 38).
Psychiatrist could be treating individual patients with
LAI or oral antipsychotic medications. Psychiatrist andA 
M
B
Patients may express 
treatment preferences 
Patient-managed on prescriber 
invitation
M
Treatment planning and LAI 
scheduling (if chosen) 
(Based on patient status, adherence 
and tolerance) 
Prescriber-managed
Probes for adherence, 
tolerability, symptoms, and 
treatment assessment* 
Prescriber-managed
Patients may offer subjective 
illness narrative
Figure 2 Observed conversation flow between: A. patients and prescpatient characteristics by type of treatment are listed in
Table 1. Median years in practice for psychiatrists trea-
ting LAI patients and those treating patients on orals
were 25 and 18 years, respectively. Patients receiving
oral treatment were predominantly female (59%) and
LAI patients were mostly male (53%). The majority of
patients across both groups (58% to 64%) were initially
diagnosed with schizophrenia >10 years prior to the
study. More than one fourth (27% to 29%) of the sample
were diagnosed within 5 years.
Treatment decisions and conversations on long-acting
injectable antipsychotics
Psychiatrists made antipsychotic treatment decisions
without patient or caregiver input during 40 of 60 (67%)
conversations. Patients with less severe impairment were
more likely to be involved in treatment decisions (con-
versations with 13 of 36 [36%] mild or moderate patients
vs 7 of 24 [29%] severe patients). Involvement in treat-
ment decisions was greater when discussing LAIs: 15 of
60 (25%) with patients/ caregivers vs decisions about
oral antipsychotics, 5 of 60 (8%). However, there were
no discussions of LAIs by psychiatrists in 11 of 22 (50%)
patients taking oral antipsychotics (Table 2), despite the
fact that participating patients were indicated for a
change in treatment. Overall, only 6 of the 60 conver-
sations (10%) involved patients actively making an anti-
psychotic treatment decision.
The conversation flow around introducing LAIs typic-
ally followed a number of steps that could be terminated
by the prescriber or patient at several decision points
(Figure 3). More than half (11 of 19 [58%]) of LAI-naïveGeneral open-ended question 
and patient response 
“What would you like to talk about?” 
anaged mutually by SW/therapist and patient
 
Goal setting and therapy planning
“What would you like to work on?” 
anaged mutually by SW/therapist and patient
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• Probes on negative symptoms and social 
  outcomes
• May check medication adherence
• Discuss finances/money management
• Discuss family life and review practical 
  living skills 
               SW/therapist-managed
ribers (n = 69); B. patients and social workers or therapists (n = 4).







(n = 22) (n = 38)
Previously treated with LAIa 3 (14) NA
Discussion of oral treatment 3 NA
Discussion of LAI treatment 3 NA
Oral with discussion of LAI 8 (36) NA
Discussion of oral treatment 8 NA
Discussion of LAI treatment 8 NA
No discussion of LAI 11 (50) NA
Discussion of oral treatment 11 NA
Discussion of LAI treatment 0 NA
LAI discontinuation NA 1 (3)
Discussion of oral treatment NA 1
Discussion of LAI treatment NA 1
LAI restart NA 2 (5)
Discussion of oral treatment NA 2
Discussion of LAI treatment NA 2
LAI-to-LAI switch NA 3 (8)
Discussion of oral treatment NA 3
Discussion of LAI treatment NA 3
New start on LAI NA 11 (29)
Discussion of oral treatment NA 9
Discussion of LAI treatment NA 11
LAI continuation NA 21 (55)
Discussion of oral treatment NA 13
Discussion of LAI treatment NA 21
LAIs used in treatment, n (%)
First-generation LAIs NA 8 (21)
Second-generation LAIs NA 30 (79)
a Discussion of history of LAI use, not restarting LAI treatment.
LAI, long-acting injectable antipsychotic.
Table 1 Psychiatrist and patient characteristics by type of
treatment






Treating psychiatrists 9 11
Years in practice, mean, (SD) 16.1 (8.5) 18.5 (8.2)
Years in practice, median 18 25
Patients
Men, n (%) 9 (41) 20 (53)
Women, n (%) 13 (59) 18 (47)
Age, y, mean 45.7 38.9
Time since diagnosis, n (%)
≥10 y 14 (64) 22 (58)
>5–10 y 1 (4.5) 5 (13)
>1–5 y 6 (27) 10 (26)
6–12 months NA 1 (3)
Unknown 1 (4.5) NA
Previous psychiatric hospitalization,
n (%)
17 (77) 33 (87)
Number of previous injections for
patients currently on LAI, mean
NA 2.69
LAI, long-acting injectable antipsychotic; SD, standard deviation; y, years.
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start treatment although just three of those who agreed
(3 of 11 [27%]) verbalized favorable responses to an LAI
(Table 3). Adherence benefit was the major verbalized
reason for accepting an LAI offer and fear of needles
was most common for refusals. Almost half of patients
offered an LAI were neutral or passive in the decision.
During these conversations, a variety of techniques were
used to encourage patient acceptance of LAI treatment,
including: personal gain to the patient (“…not having to
worry about where your pills are…”); sharing other pa-
tients’ experience (“Sometimes, patients think that this is
easier …”); or occasionally use of fear tactics (“…those
voices, those paranoid thoughts are all going to come
back. It’s just a matter of time…I can guarantee…that it
will happen”). When caregivers were present they were
supportive of psychiatrists’ choice of LAIs. However, this
was only examined with a small sample, as caregivers
were only present in 3 of 19 (16%) discussions with LAI-
naïve patients.
If the decision was made to initiate LAI treatment,
psychiatrists selected the specific LAI to prescribe with
minimal patient input. Only 1 specific LAI was discussed
in most of the “new start” conversations (7 of 11 [64%]).
Patients and caregivers confirmed in TDIs that LAI se-
lection had been made without their input and they were
generally uninformed about choices (“I don’t think there
are that many choices with [the] shot.”).When the discussion about initiating LAIs was aban-
doned by prescribers, the main reason stated was to pre-
serve a healthy, trusting therapeutic relationship with
the patient rather than risk being perceived as coercive.
Second, prescribers felt it was important to allow pa-
tients to retain autonomy to create treatment “buy-in”.
Third, prescribers felt that patients who initially rejected
LAIs could become more receptive over time and chose
to reintroduce the idea at a later date.
Barriers to initiation of long-acting injectable
antipsychotics
Patient obstacles to LAI use emerged as fear or hesita-
tion about the injections. These perceived fears most
consistently impeded LAI prescription choice. Patients
who expressed strong concern about injections often did
Ideal conversation path LAI initiation barrier
LAI therapy not 
discussed
Positive Approach:
• Benefits of LAIs
• Success stories of other
 patients 
Decompose resistance












Patient does not 
accept LAI therapy





Prescriber selects the 
specific LAI without 
patient or caregiver input
HCP responds to 
patient resistance
Step may be skipped 
if resistance is not 
expressed
Figure 3 Observed conversation decision tree for prescriber interactions with patients regarding initiation of long-acting
injectable antipsychotics.
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I don’t like needles…They freak me out, they scare me,
they hurt and I don’t like them.”). Despite multiple tac-
tics attempted by psychiatrists, the persistent refusal of
patients who expressed a strong fear and concern about
injections avoided use of LAIs. Of the 7 of 19 (37%) LAI-
naïve patients who responded unfavorably to an LAI offer
from a prescriber, only 2 of 7 (29%) received an LAI.Table 3 Patient reactions to psychiatrist’s offer of
long-acting injectable antipsychotic treatment
LAI-naïve patient reactions to
n (%)
Prescribed a LAI, n
LAI offer (n = 19) (% of reaction category)
Favorable 3 (16) 3 (100)
Neutral/passive 9 (47) 6 (67)
Unfavorable/concerned 7 (37) 2 (29)
Verbalized patient reasons for LAI acceptance (favorable)a, n
Adherence benefits 3
Extended/consistent efficacy 1
Lessen oral pill burden 1
Verbalized patient reasons for LAI refusal (unfavorable)b, n
Fear of needles 3
Dosing logistics/administration 2
Side effect concerns 2
Unclear 1
aTwo patients cited 1 other benefit in addition to adherence.
bOne patient cited 2 reasons for refusal of LAI.
LAI, long-acting injectable antipsychotic.Another barrier to LAI use was the lack of patient
insight into the disease and treatment (inability to rea-
son regarding symptoms and treatment options). Pa-
tients generalized the negative treatment experience
with a single LAI to the entire class of LAIs, even if
there was a clear distinction between that past experi-
ence and currently available options.
Other examples of potential barriers to LAIs reported
by individual patients included the requirement to go to
the CMHC to receive injections and wishing treatment
with medication was more effective. It is unknown to
what extent these reasons ultimately prevented patients
from receiving injections. In TDIs, the cost of medica-
tion as a barrier was reported in a very small number of
cases as most patients received state or federal assistance
(8 of 12 [67%]) or held private insurance (3 of 12 [25%]).
Among prescribers, possible side effects were among
the chief concerns for LAI usage, specifically, with the
long-acting effects of this administration method be-
cause treatment cannot be withdrawn rapidly if side
effects suddenly occur. Despite this concern, conversa-
tions about side effects were rarely initiated by psychia-
trists, typically being left for the patient to initiate. Even
when specific side effects were explored (eg, with the
use of general questions such as, “Have you been
sleeping okay?” or “Is your appetite okay?”), they were
not always directly attributed to the medication. Similar
to psychiatrists, NPs tended to use very general ques-
tions about side effects, and during conversations did
not always differentiate among side effects of LAIs vs.
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rare–only 4 of the 38 patients treated by psychiatrists
switched or discontinued LAI treatment: 1 discontinued
due to restless legs and other unspecified side effects,
while 3 switches to a different LAI occurred due to fa-
tigue/grogginess (n = 1) and high prolactin levels (n = 2).
It should also be noted that psychiatrists’ patients on an
LAI at time of study had previously received an average
of 2.7 injections, suggesting they had probably only re-
cently begun treatment.
Overcoming barriers to treatment with long-acting
injectable antipsychotics
Prescribers were most successful in overcoming patient
objections to LAIs by decomposing resistance to un-
cover the severity of resistance and investigate beyond
the initially stated problem to address the root issue.
Prescribers used several other logic-based approaches to
overcome barriers during discussions. Emphasizing the
benefits of newer LAIs, like the use of smaller needles
with certain injections, or better therapeutic effects with
LAIs than their oral counterparts helped patients com-
mence LAI treatment. Empowering patients during the
decision (“…just commit to one month of medicine,
that’s all, just one shot. If it’s a disaster we’ll switch
gears”), emphasizing convenience (“one shot and we can
pretty much minimize all medication”), or showing pa-
tients the needle and talking to the nurse were also suc-
cessful approaches. In terms of decomposing resistance,
one particular example included a patient who claimed
to have a fear of needles, yet was actually resistant due
to a 20-lb weight gain with a previous LAI. Digging
deeper into the objection was successful. (Patient: “I ac-
tually, I have problems with needles. …last year, [my
doctor was] giving me those [specific LAI medication]
shots and it made me gain 20 pounds in 1 week”, Psych-
iatrist: “So it wasn’t the injection, per se, it was the side
effect of the medicine. There is a different injection we
can use. This is a once a month and I have several cli-
ents on it who have not gained weight.”).
Determinants of continued use of long-acting injectable
antipsychotics
Twelve patients who received LAIs participated in TDIs;
9 of 12 (75%) believed they had improved over the
3 months during which the interviews occurred and
attributed their success mainly to their LAI treatment.
No patients reported a worsening condition. Individual
patients mentioned benefits of LAIs that included: im-
provements in symptoms, better concentration, atten-
tion, alertness, and a more positive outlook. Patients also
mentioned the medication working “faster” and “better”
than oral formulations. Generally, strong support sys-
tems and an absence of barriers kept patients adherentto the LAI schedule. As with oral medications, stable
home environments, involved family members, friends,
and other such caregivers, and case workers helped con-
tribute to adherence. Addressing logistical issues like
transportation services to enable patients to reach a
CMHC for treatment also encouraged LAI usage and
adherence.
Information seeking and communication about LAIs
may have contributed as another determinant for LAI
usage, particularly by using the Internet. Most patients
and caregivers reported using the Internet most com-
monly to search for information about schizophrenia,
with most activity occurring around the time of diag-
nosis. Additionally, a few patients and caregivers re-
ported social media sites (eg, blogs, message boards,
chat rooms) to be the most useful source of disease
information.
During TDIs, LAI patients reported willingness to
share positive experiences with other patients including
convenience, efficacy, and concerns about the injections/
needles. The above may serve as future assistance for
other patients considering LAI treatment.
Discussion
This study provided information to characterize the
process and content of prescriber-patient interactions,
perspectives around treatment with LAI antipsychotics
and prescriber strategies to overcome barriers. Although
many psychiatrists do not routinely offer LAIs to their
patients and do not involve patients in antipsychotic
treatment decision making, many patients are willing to
start LAIs due to their neutral perspectives on the mat-
ter. Decision points around starting/restarting or not
starting LAIs in this study seemed to be influenced by
the pre-established beliefs concerning LAIs for both pre-
scribers and patients; the majority of prescribers were
concerned about damaging the therapeutic relationship
and side effects. Some patients have negative feelings
about the injection, however, more LAI-naïve patients
expressed neutral rather than favorable or unfavorable
responses when offered LAIs and this presents an op-
portunity for guiding decision making and a deeper
dialogue.
One quarter (15 of 60 [25%]) of patient-prescriber
conversations were focused on LAIs, whereas only 8%
(5 of 60) were focused on orals. This finding suggests
that prescribers seemed to welcome patient involvement
in the LAI treatment decisions as much, if not more,
than oral treatment decisions. Although a minority of
patients was actively involved in final treatment deci-
sions, there seems to be room for more active patient
engagement to move past resistance through additional
assessment of patient concerns and provision of relevant
information. When patients play active roles by asking
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feel more in control of their treatment and, therefore, be
more receptive to LAIs. Prescribers may also need to
allocate more time to discussion of adherence to the
patients’ current medication as another possible me-
thod of opening conversation on use of LAIs. In the
current study, discussion of adherence to current
medication occupied only 2% of the prescriber-patient
visit. However, there may be limited time for pre-
scribers to discuss treatment options if the average
time spent with the patient is 12 minutes or less as
was found in this study.
The current study also seems to support findings that
increasing knowledge of the provider [30] and informa-
tion on positive LAI experiences of the patient [29] may
improve attitudes about LAIs and facilitate the prescrib-
ing process. Providing increased information on simpli-
city, safety, and tolerability of LAIs, and feedback of
positive experiences/outcomes could be helpful to re-
duce resistance of both prescribers and patients.
Despite guidelines suggesting that LAIs be used for
convenience or patient preference (and not exclusively
to address adherence) [20-22], there was little direct evi-
dence in the current study that LAIs were offered with
convenience as the primary determinant. Most pre-
scribers still appeared to consider LAIs best for patients
with current or potential nonadherence issues with oral
formulations, citing convenience merely as a tactic to
encourage patients to accept LAIs. Interestingly, a recent
survey showed that 64% of LAI prescriptions were based
on patient request, compared with 43% for nonadhe-
rence [28]. The survey also indicated psychiatrists would
prescribe LAIs more frequently if patients would accept
this formulation [28]; the disconnect is evident in that
nearly two-thirds of LAI-naïve patients were not even
informed of this option [28]. Increased awareness among
both doctors and patients of the option to prescribe/re-
ceive LAIs for reasons other than adherence may help
inform treatment decisions.
It should also be noted that patients in the current study
using oral medications were about 7 years older (mean
age: 45.7 years) than those taking LAIs (38.9 years). In
contrast, the Patel et al. [33] study of patient preferences
and attitudes towards LAIs found that patients on LAIs
were significantly older than patients on oral antipsy-
chotics. It is not known how age and other patient charac-
teristics impact perspectives on treatment with LAIs.
Other patient characteristics such as the effect of patient
cultural perspectives were not investigated and would be
worth further study.
Only 4 caregivers were surveyed in this study. How-
ever, results here and in the literature suggest caregiver
involvement facilitates LAI usage. During the current
study, caregivers were only present in 16% (3 of 19) ofconversations between psychiatrists and LAI-naïve pa-
tients, but in each case encouraged the use of LAIs.
Overall, there has been relatively little investigation on
caregiver attitudes about LAIs compared with those of
HCPs and patients. A PubMed search in October 2012
using the string long-acting injectable antipsychotics atti-
tudes yielded 35 articles, whereas adding the terms care-
givers or relatives yielded 2 and 4 articles, respectively.
One article indicated stronger support from caregivers
than from patients for the potential advantages of
LAIs [28].
Despite the valuable information gained in the current
study, there are some obvious limitations. The informa-
tion obtained was subjective, difficult to quantify, and
from a small, non-random sample that included few
caregivers. Accordingly, there were no formal statistical
analyses performed to compare different approaches, at-
titudes, or usage of terms during conversations, and any
direct effects on LAI usage patterns. The rate at which
HCPs prescribed oral and LAI antipsychotic formula-
tions prior to the study was not captured and it is un-
known how their prescribing trends compared with
national rates. In addition, it is possible that ethnic/racial
or primary language differences between patients and
prescribers may have influenced patients’ perceptions
and reactions during conversations; however, this in-
formation was not captured. A larger scale study with
quantifiable variables and statistical power would be use-
ful to address these limitations and to objectively identify
approaches to help both prescribers and patients make
more informed treatment decisions.Conclusions
Although some prescriber and patient perspectives on
LAIs have been described in the literature, the additional
dynamic understanding of prescriber-patient interactions
gained here by analyzing actual conversations provided
further insights. The prescriber-patient visit presents op-
portunities for deeper dialogue on the use of LAIs and
more patient and caregiver involvement in decisions
about treatment options and goals. Increasing know-
ledge about LAIs and the process of initiating treatment,
for the prescriber and patient, may facilitate use of LAIs.
For patients, this can occur when prescribers actively en-
gage the patient to move past initial resistance to LAIs.
However, more needs to be known about the effects of
patient characteristics and caregiver involvement on
treatment decisions. The process, perspectives, barriers,
and approaches identified here may help inform treat-
ment decisions when prescribing LAIs and stimulate
additional research leading to more effective indi-
vidual approaches to treatment for the patient with
schizophrenia.
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